Compare Raymond James Financial, Inc. (RJF) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Raymond James Financial, Inc. trades at $175.81 (market cap $33.96B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Raymond James Financial, Inc. is far larger — about 18.3× Recursion Pharmaceuticals Inc's market cap, and Raymond James Financial, Inc. pays a 1.22% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RJF | RXRX | |
|---|---|---|
Market Cap | $33.96B | $1.86B |
Sector | Financials | Health |
52-Week High | $181.18 | $6.79 |
52-Week Low | $140.89 | $2.84 |
Dividend Yield | 1.22% | — |
Enterprise Value | — | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $176.55, down 0.98% on the day, with a bullish earnings trend after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Recent Q3 2026 results showed record revenues of $3.93 billion, up 16% year-over-year, driven by wealth management growth and investment banking recovery.
RJF presents a compelling investment case with strong fundamentals and analyst support, though technical indicators suggest near-term caution. The consensus price target of $184.11 implies 4.3% upside potential, with no sell ratings among 25 analysts. Key risks include rising expenses and capital markets volatility, while the company's advisor recruitment momentum and dividend payments provide stability.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
